Inhibitor development in haemophilia according to concentrate: Four-year results from the European haemophilia safety surveillance (EUHASS) project

Thrombosis and Haemostasis

Volumn 113, Issue 5, 2015, Pages 968-975

  Fischer, Kathelijn ^a,b   Lassila, Riita ^c   Peyvandi, Flora ^d   Calizzani, Gabriele ^e   Gatt, Alex ^f   Lambert, Thierry ^g   Windyga, J ^k   Iorio, Alfonso ⁱ   Gilman, Estelle ^j   Makris, Michael ^j  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF MILAN   (Italy)

^e Italian National Blood Centre   (Italy)

^f MATER DEI HOSPITAL   (Malta)

^g BICÊTRE HOSPITAL   (France)

^h INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k NONE

more..

Author keywords

Adverse drug reaction reporting systems; Antibodies; Factor VIII; Haemophilia A; Haemophilia B; Neutralising

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE SURVEILLANCE; EUROPEAN; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; CHEMISTRY; DRUG SURVEILLANCE PROGRAM; EUROPE; INCIDENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; EUROPE; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INCIDENCE; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84931274723     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-10-0826     Document Type: Article

References (26)

1. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344: 1773–1779.
2. Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med 1965; 273: 1443–1447.
3. Rabiner SF, Telfer MC. Home transfusion for patients with hemophilia A. N Engl J Med 1970; 283: 1011–1015.
4. Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol 1970; 34: 111–124.
5. Gouw SC, Van der Bom JG, Van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648–4654.
6. Gouw SC, Van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046–4055.
7. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 2: 1047–1054.
8. Xi M, Makris M, Marcucci M, et al. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11: 1655–1662.
9. Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol 2006; 13: 316–322.
10. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256–1265.
11. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasmaproduct exposed toddlers). Haemophilia 2007; 13 (Suppl 5): 65–68.
12. Gouw SC, Van der Bom JG, Ljung R, et al.. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231–239.
13. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180–2192.
14. Hay CR, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367–6370.
15. Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 (Suppl 2): S22-S25.
16. Fischer K, Lewandowski D, Van den Berg HM, et al. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia 2012; 18: e241-e246.
17. Wilson EB. Probable influence, the law of succession, and statistical inference. J Am Stat Ass 1927; 22: 209–212.
18. Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998; 147: 783–790.
19. Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954–1962.
20. Mancuso ME, Mannucci PM, Rocino A, et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10: 781–790.
21. Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factorVIII for treatment of previously untreated or minimally treated young children with severe haemophilia A. Thromb Haemost 2005; 93: 457–67.
22. Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39: 752–766.
23. Iorio A, Matino D, D’Amico R, Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2010 Aug 4; 8: CD004449.
24. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576–2581.
25. Puetz J, Soucie JM, Kempton CL, et al. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia 2014; 20: 25–31.
26. Soucie JM. Occurrence of haemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59: 188–194.